Skip to main content
. 2023 May 25;83(9):825–831. doi: 10.1007/s40265-023-01885-6

Key clinical trials of zavegepant sponsored by Biohaven Pharmaceuticals

Drug(s) Indication Phase Status Location(s) Identifier
Zavegepant, placebo Migraine 3 Completed USA NCT04571060; BHV3500-301
Zavegepant, placebo Migraine 2/3 Completed USA NCT03872453; BHV3500-201
Zavegepant Migraine 2/3 Completed USA NCT04408794; BHV3500-202
Zavegepant, placebo Migraine 2/3 Recruiting USA NCT04804033; BHV3500-302